JP2021525225A5 - - Google Patents

Info

Publication number
JP2021525225A5
JP2021525225A5 JP2020551516A JP2020551516A JP2021525225A5 JP 2021525225 A5 JP2021525225 A5 JP 2021525225A5 JP 2020551516 A JP2020551516 A JP 2020551516A JP 2020551516 A JP2020551516 A JP 2020551516A JP 2021525225 A5 JP2021525225 A5 JP 2021525225A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
sde
diisopropyl adipate
caprylic
Prior art date
Application number
JP2020551516A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021525225A (ja
JPWO2019191511A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/024706 external-priority patent/WO2019191511A1/en
Publication of JP2021525225A publication Critical patent/JP2021525225A/ja
Publication of JP2021525225A5 publication Critical patent/JP2021525225A5/ja
Publication of JPWO2019191511A5 publication Critical patent/JPWO2019191511A5/ja
Pending legal-status Critical Current

Links

JP2020551516A 2018-03-29 2019-03-28 掻痒症を治療するための組成物及び方法 Pending JP2021525225A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862650108P 2018-03-29 2018-03-29
US62/650,108 2018-03-29
PCT/US2019/024706 WO2019191511A1 (en) 2018-03-29 2019-03-28 Compositions and methods for treating pruritus

Publications (3)

Publication Number Publication Date
JP2021525225A JP2021525225A (ja) 2021-09-24
JP2021525225A5 true JP2021525225A5 (https=) 2022-04-11
JPWO2019191511A5 JPWO2019191511A5 (https=) 2022-04-11

Family

ID=68054657

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020551516A Pending JP2021525225A (ja) 2018-03-29 2019-03-28 掻痒症を治療するための組成物及び方法

Country Status (13)

Country Link
US (2) US20190298702A1 (https=)
EP (1) EP3755328A4 (https=)
JP (1) JP2021525225A (https=)
KR (1) KR20200138730A (https=)
CN (1) CN112040948A (https=)
AU (1) AU2019243571A1 (https=)
BR (1) BR112020019094A2 (https=)
CA (1) CA3094710A1 (https=)
IL (1) IL277463A (https=)
MX (1) MX2020009813A (https=)
RU (1) RU2020130919A (https=)
TW (1) TWI729371B (https=)
WO (1) WO2019191511A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113797167B (zh) * 2020-06-16 2024-05-10 苏州恩华生物医药科技有限公司 一种塞纳布啡的储库制剂
CA3186630A1 (en) * 2020-06-30 2022-01-06 Dermira, Inc. Irak4 inhibitors and topical uses thereof
WO2022175973A1 (en) * 2021-02-18 2022-08-25 Navin Saxena Research And Technology Private Limited An injectable composition for long term delivery of nalbuphine or nalbuphine ester prodrug or its salts and use thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL130759C (https=) * 1965-10-07
US5229130A (en) * 1991-12-20 1993-07-20 Cygnus Therapeutics Systems Vegetable oil-based skin permeation enhancer compositions, and associated methods and systems
US6225321B1 (en) * 1997-06-05 2001-05-01 Oliver Yoa-Pu Hu Long analgesic acting nalbuphine polyester derivative and method of use
US6503944B1 (en) * 1999-05-26 2003-01-07 The Andrew Jergens Company Anhydrous skin care composition
US6967023B1 (en) * 2000-01-10 2005-11-22 Foamix, Ltd. Pharmaceutical and cosmetic carrier or composition for topical application
ES2188481T3 (es) * 2000-04-27 2003-07-01 Oliver Yoa-Pu Hu Derivados de polinalbufina.
US20080069779A1 (en) * 2003-08-04 2008-03-20 Foamix Ltd. Foamable vehicle and vitamin and flavonoid pharmaceutical compositions thereof
US20070093517A1 (en) * 2005-10-24 2007-04-26 Gary Newton Local anesthetic compositions
CA2788440A1 (en) * 2010-02-26 2011-09-01 Xenon Pharmaceuticals Inc. Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
EP2788028B1 (en) * 2011-12-08 2019-03-27 Rigel Pharmaceuticals, Inc. Topical formulation for administering a compound
US20140112957A1 (en) * 2012-10-19 2014-04-24 Oliver Yao-Pu Hu Analegisic (Sebacoyl dinalbuphine ester) PLGA controlled release formulation form
MX2016016404A (es) * 2014-06-13 2017-11-30 Trevi Therapeutics Inc Metodos para el tratamiento del prurito.
EP3302477B1 (en) * 2015-05-28 2024-02-07 Lumosa Therapeutics Co., Ltd. Pharmaceutical formulations for sustained release of sebacoyl dinalbuphine ester

Similar Documents

Publication Publication Date Title
JP7324210B2 (ja) トファシチニブを含む局所製剤
US8293790B2 (en) Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
KR100619228B1 (ko) 국소피부전달 무수조성물 및 상기 조성물을 약제로 포함하는 국소 피부 치료용 조성물
EP2450035B1 (en) Combination of adapalene and benzoyl peroxide for treating acne lesions
AU2019200064A1 (en) Topical compositions of flunisolide and methods of treatment
JP7578651B2 (ja) ジアセレインまたはレインの局所製剤およびその使用
US20160287614A1 (en) Stable Pharmaceutical Formulation(s) of Tetracycline Antibiotic
US20200345671A1 (en) Topical pharmaceutical composition of adapalene and minocycline
CN101972225A (zh) 一种含吡非尼酮的凝胶组合物
JP2021525225A5 (https=)
RU2020130919A (ru) Композиции и способы для лечения зуда
US10123970B2 (en) Topical retinoid solutions
US8524774B1 (en) Topical two step polytherapy for treatment of psoriasis and other skin disorders
US12491192B2 (en) Compositions and methods for the topical administration of spironolactone for the treatment of cutaneous signs of excess androgen and chronic stress response
JPWO2019191511A5 (https=)
EP2505195B1 (en) Topical pharmaceutical compositions of ketoprofen and methylsulfonylmethane
US20130197089A1 (en) Compositions for the treatment of actinic keratosis
US10022348B2 (en) Topical solution of isotretinoin
US20200230082A1 (en) Topical acetaminophen formulations for itch relief
CA3118698A1 (en) Teriflunomide topical pharmaceutical compositions
JP7514598B2 (ja) 皮膚外用組成物
CN118662507A (zh) 一种改善黄褐斑的外用组合物
BG65352B1 (bg) Средство за лечение на псориазис
CA3174475A1 (en) Topical pharmaceutical formulations of a cyclic depsipeptide
KR20150128952A (ko) 플루니솔리드의 국소 조성물 및 치료 방법